U.S. Securities And Exchange Commission
                             Washington, D.C. 20549

                                    Form 8-K


                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


                                                                             


                           ELITE PHARMACEUTICALS, INC.
 ....................................................................................................................
             (Exact name of registrant as specified in its charter)


                         333-45241                                             22-3542636
 ....................................................................................................................
                  (Commission File Number)                        (I.R.S. Employer Identification No.)

 ....................................................................................................................
     165 Ludlow Avenue, Northvale, New Jersey                                   07647
 ....................................................................................................................
           (Address of principal executive office)                             (Zip Code)

                                                   (201) 750-2646
 ....................................................................................................................
               Registrant's telephone number, including area code



 ....................................................................................................................
                           (Former Name or Former Address, if Changed Since Last Report)
 ...................................................................................................................



Item 5.   Other Events

         The Company  recently  concluded a private  placement of its securities
resulting in the  issuance of  1,275,002  shares of its common stock and 637,501
warrants.  The  private  placement  resulted  in net  proceeds to the Company of
$4,452,500.

         The  information  set  forth  in the  press  release  issued  by  Elite
Pharmaceuticals, Inc. attached hereto as Exhibit 99.1, is incorporated herein by
reference.


Item 7.   Financial Statements, Pro Forma Financial Statements and Exhibits

     (c)  Exhibits

          99.1 Press release of Elite Pharmaceuticals, Inc. dated July 8,  1999.




                                    SIGNATURE


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                     ELITE PHARMACEUTICALS, INC.



                                                    By:
                                                    Mark I. Gittelman, Treasurer



Date: August 4, 1999














                                  EXHIBIT INDEX


Item No.

99.1 Press release of Elite Pharmaceuticals, Inc. dated July 8, 1999.
















































                                        3